Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients
| Autor: | Stefano Cordio, Gerardo Rosati, Roberto Bordonaro, A. Tucci, Giorgio Reggiardo, Giuseppina Blanco, Luigi Manzione |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Organoplatinum Compounds medicine.drug_class Colorectal cancer Leucovorin Tegafur/uracil Administration Oral Tegafur Antimetabolite Gastroenterology Metastasis Folinic acid Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Neoplasm Metastasis Infusions Intravenous Uracil Aged Aged 80 and over business.industry Age Factors General Medicine medicine.disease Oxaliplatin Clinical trial Treatment Outcome Oncology Female business Colorectal Neoplasms medicine.drug |
| Zdroj: | Oncology. 69(2) |
| ISSN: | 0030-2414 |
| Popis: | Objectives: Colorectal cancer is usually diagnosed in elderly patients. Since there is clear evidence that such patients are under-treated and under-represented or even excluded from clinical studies and there are no reliable and prospective data on the feasibility and efficacy of an oxaliplatin (L-OHP)-based chemotherapy in this setting, we have tested the L-OHP plus oral uracil/tegafur (UFT) and oral folinic acid (FA) combination as first-line therapy in patients with advanced or metastatic colorectal cancer (MCRC) aged 70 or older. Patients and Methods: Forty-seven patients with advanced or MCRC, aged over 70, were treated with L-OHP 65 mg/m2 as an intravenous 3-hour infusion on day 1 and 8 plus UFT 300 mg/m2 and FA 90 mg in 3 divided doses given orally on days 1–14 for each 3-week cycle. Patients were followed by a geriatric and a quality of life (QoL) assessment with specific scales and EORTC-QLQ-C30 questionnaire. Results: All patients were assessable for toxicity and 45 for response to treatment. Complete response was achieved in 2 patients (4%) and partial response in 22 (47%) [overall response rate, 51%; 95% confidence interval (CI): 40.7–61.2%]; 18 patients (38%) had stable disease, and 5 (11%) had disease progression. The median duration of response was 8 months (range, 3–19+ months). After a minimum follow-up of 17 months, the median time to disease progression and the median overall survival were 8.0 (95% CI: 6.7–9.3%) and 14.1 (95% CI: 11.0–17.1%) months, respectively. Regimen safety was manageable. Most adverse events were mild to moderate, and this did not result in QoL impairment. The most common grade 3–4 treatment-related adverse events were diarrhea (17%), neutro- and thrombocytopenia (2%), laryngeal spasm (2%), and peripheral neuropathy (12.7%). No treatment-related deaths occurred. Conclusions: These results confirmed that this tested chemotherapy combination is active with acceptable tolerability and QoL maintenance in elderly patients with advanced or MCRC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|